Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anal gland carcinoma.

C M Hobbs1, M A Lowry, D Owen

  • 1Department of Hepatic and Gastrointestinal Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA.

Cancer
|October 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, London, Ont., Sept. 19 to 22, 2002.

Canadian journal of surgery. Journal canadien de chirurgie·2023
Same author

NEW DEFINITIVE HOST RECORD FOR CHORDODES MORGANI (NEMATOMORPHA) IN NEBRASKA WITH NOTES ON ECOLOGY.

The Journal of parasitology·2021
Same author

Response to Kibe Y et al. "Methodological concerns for investigating the effects of midtreatment break of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC)".

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2020
Same author

A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2019
Same author

Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS).

BMC neurology·2017
Same author

Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [<sup>11</sup>C]PBR28 PET study.

Translational psychiatry·2017

Anal gland carcinoma is a rare cancer. This study defines it as an anal canal tumor with specific gland characteristics and invasion, aiding in diagnosis.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pathology

Background:

  • Anal gland carcinoma is a rare malignancy.
  • This study reviewed archival cases from the Armed Forces Institute of Pathology and the Canadian Reference Center for Cancer Pathology.

Purpose of the Study:

  • To establish a precise definition for anal gland carcinoma.
  • To differentiate anal gland carcinoma from other anorectal tumors using histological and immunohistochemical markers.

Main Methods:

  • Reviewed 19 archival cases of potential anal gland carcinoma.
  • Conducted clinical, histological, and immunohistochemical analyses on 14 suitable cases.
  • Applied a modified World Health Organization (WHO) definition for diagnosis.

Main Results:

Related Experiment Videos

  • Seven cases met the modified WHO definition for anal gland carcinoma.
  • These tumors exhibited haphazardly dispersed small glands invading the anorectal wall without intraluminal components.
  • Immunohistochemistry showed cytokeratin (CK) 7+/CK 20- expression in most confirmed cases.
  • Other cases included mucinous adenocarcinomas and rectal-type adenocarcinomas with varying CK profiles.

Conclusions:

  • Anal gland carcinoma is defined by specific histological features: haphazard small glands, scant mucin, wall invasion, and absence of intraluminal component.
  • Cytokeratin 7 (CK 7) positivity is a key immunohistochemical marker.
  • This definition aids in distinguishing anal gland carcinoma from other anorectal tumors.